HRS-6209

DRUG2 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Shandong Suncadia Medicine Co., Ltd.

Conditions

Advanced Solid TumorsAdvanced Unresectable or Metastatic Breast Cancer

Phase 1

A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors

Active, not recruitingNCT05781048

Jiangsu HengRui Medicine Co., Ltd.Advanced Solid Tumors

Start: 2023-03-23End: 2026-12-30Updated: 2026-03-10

A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients

RecruitingNCT06679036

Shandong Suncadia Medicine Co., Ltd.Advanced Unresectable or Metastatic Breast Cancer

Start: 2025-01-21End: 2026-12-31Target: 300Updated: 2026-03-02